Wound healing and treatment of fibrosis

• US 7,566,446 B2
• Filed: 10/02/2006
• Issued: 07/28/2009
• Est. Priority Date: 12/04/1996
• Status: Expired due to Fees

• Current Assignee: Renovo Ltd. (Bentley Park Ltd.)
• Original Assignee: Renovo Ltd. (Bentley Park Ltd.)
• Inventors: O'Kane, Sharon, Ferguson, Mark W. J.
• Primary Examiner(s): SCHNIZER, RICHARD A
• Application Number:
  US11/540,956
• Publication Number:
  US 20070087969A1
• Time in Patent Office: 1,030 Days
• Field of Search: None
• US Class Current: 424/78.06
• CPC Class Codes: A61K 38/1709 from mammals
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 27/02 Ophthalmic agents

Abstract

Compositions for use in the treatment of wounds and fibrosis comprising a therapeutically effective amount of a compound that modulates actin assembly and organization intracellularly and/or extracellularly and a pharmaceutically acceptable vehicle; such a compound promotes the rate of wound healing and also prevents or reduces fibrosis. A preferred compound is gelsolin.

Claims

1. A method of reducing scar formation in incisional dermal wounds, the method comprising delivering directly to a dermal wound in need of such treatment a therapeutically effect amount of a regulatory protein that caps the fast growing end of actin filaments and/or severs capped actin filaments so that said scar formation is reduced.

2. The method according to claim 1 wherein the regulatory protein is selected from the group consisting of gelsolin, villin, CapG, adseverin, flightless-1, advillin and amino acid deletion or amino acid addition derivatives thereof.

3. The method according to claim 2 wherein the regulatory protein is gelsolin or an amino acid deletion or amino acid addition derivative thereof.

4. The method according to claim 1 wherein the regulatory protein is selected from the group consisting of gelsolin, villin, CapG, adseverin, flightless-1 and advillin.

5. The method according to claim 4 wherein the regulatory protein is gelsolin.